Cargando…

Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance

Kinin B1 receptor (B1R) contributes to insulin resistance, an early event in type 2 diabetes, through the upregulation and activation of the inducible form of nitric oxide synthase (iNOS), pro-inflammatory cytokines and the oxidative stress. This study addresses the hypothesis that inhibition of kin...

Descripción completa

Detalles Bibliográficos
Autores principales: Haddad, Youssef, Couture, Réjean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539221/
https://www.ncbi.nlm.nih.gov/pubmed/28824433
http://dx.doi.org/10.3389/fphar.2017.00509
_version_ 1783254445337870336
author Haddad, Youssef
Couture, Réjean
author_facet Haddad, Youssef
Couture, Réjean
author_sort Haddad, Youssef
collection PubMed
description Kinin B1 receptor (B1R) contributes to insulin resistance, an early event in type 2 diabetes, through the upregulation and activation of the inducible form of nitric oxide synthase (iNOS), pro-inflammatory cytokines and the oxidative stress. This study addresses the hypothesis that inhibition of kininase 1 (carboxypeptidase M, CPM), the key enzyme involved in the biosynthesis of B1R agonists, could exert the same beneficial effects to B1R antagonism in insulin resistance. Male Sprague-Dawley rats were made insulin resistant with a drinking solution containing 10% D-glucose for a period of 9 weeks. Control rats received tap water. During the last week, kininase 1 was blocked with Mergetpa (1 mg kg(−1) twice daily, s.c.) and the impact was determined on insulin resistance (HOMA index), metabolic hormone levels, oxidative stress and the expression of several markers of inflammation by western blot and qRT-PCR. Glucose-fed rats displayed hyperglycemia, hyperinsulinemia, hyperleptinemia, insulin resistance, hypertension, positive body weight gain, and enhanced expression of B1R, CPM, iNOS, and IL-1β in renal cortex, aorta and liver. Markers of oxidative stress (superoxide anion and nitrotyrosine expression) were also enhanced in aorta and renal cortex. Mergetpa reversed and normalized most of those alterations, but failed to affect leptin levels and hypertension. Pharmacological blockade of kininase 1 (CPM) exerted similar beneficial effects to a 1-week treatment with a B1R antagonist (SSR240612) or an iNOS inhibitor (1,400 W). These data reinforce the detrimental role of B1R in insulin resistance and recommend CPM as a new therapeutic target.
format Online
Article
Text
id pubmed-5539221
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-55392212017-08-18 Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance Haddad, Youssef Couture, Réjean Front Pharmacol Pharmacology Kinin B1 receptor (B1R) contributes to insulin resistance, an early event in type 2 diabetes, through the upregulation and activation of the inducible form of nitric oxide synthase (iNOS), pro-inflammatory cytokines and the oxidative stress. This study addresses the hypothesis that inhibition of kininase 1 (carboxypeptidase M, CPM), the key enzyme involved in the biosynthesis of B1R agonists, could exert the same beneficial effects to B1R antagonism in insulin resistance. Male Sprague-Dawley rats were made insulin resistant with a drinking solution containing 10% D-glucose for a period of 9 weeks. Control rats received tap water. During the last week, kininase 1 was blocked with Mergetpa (1 mg kg(−1) twice daily, s.c.) and the impact was determined on insulin resistance (HOMA index), metabolic hormone levels, oxidative stress and the expression of several markers of inflammation by western blot and qRT-PCR. Glucose-fed rats displayed hyperglycemia, hyperinsulinemia, hyperleptinemia, insulin resistance, hypertension, positive body weight gain, and enhanced expression of B1R, CPM, iNOS, and IL-1β in renal cortex, aorta and liver. Markers of oxidative stress (superoxide anion and nitrotyrosine expression) were also enhanced in aorta and renal cortex. Mergetpa reversed and normalized most of those alterations, but failed to affect leptin levels and hypertension. Pharmacological blockade of kininase 1 (CPM) exerted similar beneficial effects to a 1-week treatment with a B1R antagonist (SSR240612) or an iNOS inhibitor (1,400 W). These data reinforce the detrimental role of B1R in insulin resistance and recommend CPM as a new therapeutic target. Frontiers Media S.A. 2017-08-02 /pmc/articles/PMC5539221/ /pubmed/28824433 http://dx.doi.org/10.3389/fphar.2017.00509 Text en Copyright © 2017 Haddad and Couture. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Haddad, Youssef
Couture, Réjean
Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance
title Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance
title_full Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance
title_fullStr Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance
title_full_unstemmed Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance
title_short Kininase 1 As a Preclinical Therapeutic Target for Kinin B(1) Receptor in Insulin Resistance
title_sort kininase 1 as a preclinical therapeutic target for kinin b(1) receptor in insulin resistance
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5539221/
https://www.ncbi.nlm.nih.gov/pubmed/28824433
http://dx.doi.org/10.3389/fphar.2017.00509
work_keys_str_mv AT haddadyoussef kininase1asapreclinicaltherapeutictargetforkininb1receptorininsulinresistance
AT couturerejean kininase1asapreclinicaltherapeutictargetforkininb1receptorininsulinresistance